Pleco Therapeutics has initiated a sponsored research program at The University of Texas MD Anderson Cancer Center based upon intellectual property developed at MD Anderson and licensed by Pleco. Despite the ongoing Covid pandemic, Pleco Therapeutics is now taking the next step in developing innovative treatments for leukemia patients. MD Anderson is based in Houston, Texas and ranks as one of the world’s most respected centers focused on cancer patient care, research, education and prevention.